Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume Sells 500 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares of the company’s stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Charles River Laboratories International Stock Up 1.5%

CRL stock opened at $141.00 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The company has a market capitalization of $6.93 billion, a price-to-earnings ratio of 940.00, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The stock has a fifty day moving average of $135.43 and a 200-day moving average of $164.97.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter last year, the company earned $2.27 EPS. The firm’s revenue was down 2.7% compared to the same quarter last year. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Barclays increased their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the company an “equal weight” rating in a research report on Thursday, May 8th. TD Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 target price for the company in a research report on Wednesday. Mizuho decreased their target price on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a research report on Wednesday, April 9th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price for the company in a research report on Monday, March 3rd. Finally, Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $172.31.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CRL. D1 Capital Partners L.P. bought a new position in Charles River Laboratories International in the 4th quarter worth about $172,752,000. Goldman Sachs Group Inc. boosted its position in shares of Charles River Laboratories International by 407.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 997,488 shares of the medical research company’s stock valued at $150,142,000 after acquiring an additional 800,762 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Charles River Laboratories International by 1,721.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company’s stock valued at $85,811,000 after acquiring an additional 538,792 shares during the last quarter. Norges Bank bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $98,886,000. Finally, Royal Bank of Canada boosted its position in shares of Charles River Laboratories International by 304.7% during the 1st quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company’s stock valued at $94,484,000 after acquiring an additional 472,606 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).